• Explore /
  • Poster
  • / Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.

Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.

Abstract Poster

Authors

null

Shunji Takahashi

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Shunji Takahashi , Hirofumi Mukai , Hirotsugu Uemura , Hiroji Uemura , Takeo Kosaka , Hiroyuki Nishiyama , Kazuhiro Suzuki , Yoshiyuki Kakehi , Koji Okihara , Shunichi Namiki , Osamu Ogawa , Masashi Kato , Yasutomo Nakai , Keiji Ohno

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01324583

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 237)

DOI

10.1200/jco.2014.32.4_suppl.237

Abstract #

237

Poster Bd #

D5

Abstract Disclosures

Similar Posters

First Author: Cora N. Sternberg

First Author: Matthew Raymond Smith

First Author: Constance Thibault

First Author: Rahul Raj Aggarwal